

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application No.	10/773,678
Filing Date	02/06/2004
First Named Inventor	James G. Karras
Art Unit	1635
Examiner Name	Bowman, Amy Hudson
Attorney Docket Number	23546-09725 ISPH-0828

Submitted 6/24/05

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document No. Number - Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
ATB	1	US-6,727,084	04-27-2004	Hoyoux, et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
ATB	2	WO 00/61602	10-19-2000	Isis Pharmaceuticals, Inc.	

OTHER REFERENCES - NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
ATB	3	KONNIKOVA, et al. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells, BMC Cancer, September 2003, vol. 3, pages 1-9.	
	4	ABERG, et al., Selective Introduction of Antisense Oligonucleotides into Single Adult CNS Progenitor Cells Using Electroporation Demonstrates the Requirement of STAT3 Activation for CNTF-Induced Gliogenesis, Molecular and Cellular Neuroscience, 2001; Vol. 17, pages 426-443.	
	5	PCT International Search Report and Written Opinion for International application number PCT/US04/32130, filed September 30, 2004. Search report dated April 25, 2005. 8 pages	


Examiner Signature		Date Considered	8/9/05
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible, ⁶Applicant is to place a check mark here if English language Translation is attached.

23546/09725/SF/5146013.1



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 14

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/773,678
Filing Date	February 6, 2004
First Named Inventor	James G. Karras
Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	ISPH-0828

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/773,678
Filing Date	February 6, 2004
First Named Inventor	James G. Karras
Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	ISPH-0828

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AttB	AE	AGRAWAL, S., "Antisense oligonucleotides: towards clinical trials," <i>TIBTECH</i> (1996) 14(10):376-387.	
	AF	BARTON, B. E. et al., "Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines," <i>Mol. Cancer Ther.</i> (2004) 3(1): 11-20.	
	AG	BRAASCH, D. A. et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochem.</i> (2002) 41(14): 4503-4510.	
	AH	BRANCH, A. D., "A good antisense molecule is hard to find," <i>TIBS</i> (1998) 23(2): 45-50.	
	AI	EPLING-BURNETTE, P. K. et al., "Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression," <i>J. Clin. Invest.</i> (2001) 107(3): 351-361.	
	AJ	GEWIRTZ, A. M. et al., "Facilitating oligonucleotide delivery: Helping antisense deliver on its promise," <i>Proc. Natl. Acad. Sci. USA</i> (1996) 93: 3161-3163.	
	AK	GRANDIS, J. R. et al., "Requirement of Stat3 but not Stat1 Activation for Epidermal Growth Factor Receptor-mediated Cell Growth In Vitro," <i>J. Clin. Invest.</i> (1998) 102(7): 1385-1392.	
	AL	KARRAS, J. G. et al., "STAT3 Regulates the Growth and Immunoglobulin Production of BCL ₁ B Cell Lymphoma through Control of Cell Cycle Progression," <i>Cell. Immunol.</i> (2000) 202:124-135.	
	AM	LAMY, T. et al., "Dysregulation of CD95/CD95 Ligand-Apoptotic Pathway in CD3 ⁺ Large Granular Lymphocyte Leukemia," <i>Blood</i> (1998) 92(12): 4771-4777.	
	AN	LIU, H. et al., "Serine phosphorylation of STATE3 is essential for Mcl-1 expression and macrophage survival," <i>Blood</i> (2003) 102(1): 344-352.	
	AO	MAHBOUBI, K. et al., "Desensitization of Signaling by Oncostatin M in Human Vascular Cells Involves Cytoplasmic Tyr Residue 759 in gp130 but Is Not Mediated by Either Src Homology 2 Domain-containing Tyrosine Phosphatase 2 or Suppressor of Cytokine Signaling 3," <i>J. Biol. Chem.</i> (2003) 278(27): 25014-25023.	
✓	AP	MORA, L. B. et al., "Constitutive Activation of Stat3 in Human Prostate Tumors and Cell Lines: Direct Inhibition of Stat3 Signaling Induces Apoptosis of Prostate Cancer Cells," <i>Cancer Res.</i> (2002) 62(22): 6659-6666	

Examiner
Signature

Att. Bowman

Date
Considered

8/9/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/773,678
Filing Date	February 6, 2004
First Named Inventor	James G. Karras
Art Unit	1635
Examiner Name	Amy Hudson Bowman
Attorney Docket Number	ISPH-0828

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ATH	AQ	NIU, G. et al., "Gene Therapy with Dominant-negative Stat3 Suppresses Growth of the Murine Melanoma B16 Tumor <i>In Vivo</i> ," <i>Cancer Res.</i> (1999) 59: 5059-5063.	
	AR	NIU, G. et al., "Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis," <i>Oncogene</i> (2002) 21(13): 2000-2008.	
	AS	SONG, L. et al., "Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells," <i>Oncogene</i> (2003) 22(27): 4150-4165.	
	AT	TAMM, I. et al., "Antisense therapy in oncology: new hope for an old idea?" <i>Lancet</i> (2001) 358: 489-497.	
	AU	CHIN, ANDREW "On the Preparation and Utilization of Isolated and Purified Oligonucleotides." Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on March 14, 2002.	

Examiner
Signature

ATH

Date
Considered

8/9/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.